Intersectoral costs of pneumococcal diseases: a systematic review of partial economic evaluation studies [0.03%]
肺炎球菌病的业际成本：部分经济评价研究的系统综述
Emad Almomani,Ingeborg Maria van der Putten,Ghislaine van Mastrigt et al.
Emad Almomani et al.
Introduction: This systematic review explores the intersectoral costs associated with pneumococcal diseases across different age groups and related impacts on societal costs. ...
The Economics of prevention and quality of care: policy insights from the EU's COVID-19 response [0.03%]
预防和护理质量的经济学：欧盟COVID-19应对措施的政策启示
John Yfantopoulos,Athanasios Chantzaras
John Yfantopoulos
Introduction: Prevention and quality of care are increasingly recognized as fundamental drivers of sustainable, high-performing health systems. Both have demonstrated cost-effectiveness and long-term benefits, yet remain ...
Lakshmi Nagendra,Manju Chandran,Mickael Hiligsmann
Lakshmi Nagendra
Introduction: Osteoporosis-related fractures represent a significant and growing public health concern, especially in aging populations. Despite the availability of effective treatments, significant care gaps persist in b...
Multicenter, cross-sectional study of the economic burden of multiple sclerosis and cost-driving factors [0.03%]
多中心横断面研究：多发性硬化症的经济负担及影响成本的因素
Moustafa Berrichi,Zahira Barka-Bedrane,Ahlam Osmani et al.
Moustafa Berrichi et al.
Background: Multiple sclerosis (MS) is a chronic neurodegenerative disease impacting young adults, reducing quality of life and imposing economic burdens. ...
TearCare system versus cyclosporine ophthalmic emulsion for the treatment of moderate-to-severe meibomian gland disease associated dry eye disease in the United States: a cost-utility analysis [0.03%]
泪然系统与环孢素滴眼液治疗美国伴发中重度睑板腺疾病的干眼病患者的成本效用分析
Nathan Lighthizer,Bonnie-Kim Schwertz,Thomas Chester et al.
Nathan Lighthizer et al.
Background: Meibomian gland disease (MGD) is a leading cause of dry eye disease (DED), yet current treatments like over-the-counter and prescription drops provide only symptomatic relief. TearCare is an FDA-cleared, in-of...
Robot-assisted medication management in home care and long-term care settings: a mixed-Method systematic review [0.03%]
机器人辅助居家护理和长期护理中的药物管理：系统综述
Maryam Maleki,Abbas Mardani,Edris Kakemam et al.
Maryam Maleki et al.
Introduction: Medication errors and non-adherence among older adults in home and long-term care settings are significant concerns driven by factors such as polypharmacy, cognitive decline, and caregiver burden. Emerging t...
Cost effectiveness of non-pharmacological interventions for fatigue in patients with long-term conditions: a systematic literature review [0.03%]
改善慢性疾病患者的非药物疲劳干预措施的成本效益：系统评价
Sarah Davis,Mon Mon-Yee,Anthea Sutton et al.
Sarah Davis et al.
Introduction: We aimed to assess the cost-effectiveness of non-pharmacological interventions for fatigue in patients with chronic conditions in the UK. Me...
A review of methodological aspects of economic evaluations used in NICE assessments for treatments in metastatic breast cancer [0.03%]
乳腺癌经济评估方法概述用于NICE评估治疗方法转移性乳腺癌
Jeroen Hendrikus Jacobus Paulissen,Sharon Wolters,Arjan Jacobus Postma et al.
Jeroen Hendrikus Jacobus Paulissen et al.
Introduction: Methodological choices need to be made during model development. These choices can influence the outcome of a National Institute for Health and Care Excellence (NICE) assessment. ...
Real-world evidence of first-line osimertinib effectiveness in Bulgarian patients: a retrospective analysis [0.03%]
奥希替尼一线治疗的现实世界疗效分析：保加利亚患者的回顾性研究
Manoela Manova,Boryana Ivanova,Jeliazko Arabadjiev et al.
Manoela Manova et al.
Background: Third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) osimertinib is approved as first-line treatment against non-small-cell lung cancer (NSCLC) harboring sensitizing EGFR mutations. Herein, we perform re...
Switching hemophilia a patients to an extended half-life agent on a prophylactic basis: an economic appraisal [0.03%]
switching hemophilia a患者的长期治疗药物经济评估
Konstantinos Drakos,Ariston Karagiorgis,Olga Katsarou et al.
Konstantinos Drakos et al.
Background: Gaining an understanding of transitioning hemophilia patients to an extended half-life (EHL) agent requires real-world data, encompassing various outcomes, which would help assessing the impact of the switch, ...